MiNK Therapeutics (INKT) Free Cash Flow (2020 - 2026)
MiNK Therapeutics (INKT) posted Free Cash Flow of -$1.7 million for Q1 2026, up 16.45% sequentially from -$2.1 million in Q4 2025, and down 29.21% YoY from -$2.4 million in Q1 2025.
MiNK Therapeutics (INKT) Free Cash Flow (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$1.7 million in Q1 2026.
- Quarterly Free Cash Flow fell 29.21% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.3 million (up 24.39% YoY) and the FY2025 annual result came in at -$5.9 million, up 37.99% from the prior year.
- Free Cash Flow advanced to -$1.7 million in Q1 2026 per INKT's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$941348.0 in Q3 2025 and troughed at -$5.7 million in Q3 2022.
- A 5-year average of -$3.1 million and a median of -$3.0 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 167.82% in 2022, then surged 68.57% in 2025.
- Over 5 years, Free Cash Flow stood at -$4.6 million in 2022, then soared by 33.4% to -$3.0 million in 2023, then jumped by 43.09% to -$1.7 million in 2024, then slipped by 20.03% to -$2.1 million in 2025, then gained by 16.45% to -$1.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.7 million, -$2.1 million, and -$941348.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.08 Mn |
| Jun 30, 2026 | -2.08 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Mar 31, 2026 | -1.73 Mn |
| Dec 31, 2025 | -2.07 Mn |
| Dec 31, 2025 | -2.07 Mn |
| Sep 30, 2025 | -941,348.00 |
| Sep 30, 2025 | -941,348.00 |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.29 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Mar 31, 2024 | -2.54 Mn |